Loading...
Loading...
NRBO| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 1.0K |
| Gross Profit | -1.0K |
| Operating Expense | 2,520.0K |
| Operating I/L | -2,520.0K |
| Other Income/Expense | -84.0K |
| Interest Income | 0.0K |
| Pretax | -2,604.0K |
| Income Tax Expense | 84.0K |
| Net Income/Loss | -2,688.0K |
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company specializing in therapies for neurodegenerative, infectious, and cardiometabolic diseases. The company's key therapeutic programs include ANA001, an oral niclosamide formulation in Phase 2/3 clinical trials for moderate COVID-19, NB-01 for painful diabetic neuropathy, NB-02 for cognitive impairment and neurodegenerative diseases associated with tau protein malfunction, and Gemcabene for acute COVID-19 indications.
